• Neurizon expanded Regimen I of the HEALEY ALS Platform Trial to 240 participants from 160, targeting a stronger dataset for NUZ-001.
• Topline results have not been presented; last participant dosing is now expected in Q2 2027, with topline data due early Q3 2027.
• The change aims to preserve the study’s ability to deliver a clear primary endpoint readout, with broader subgroup and biomarker analysis.
• Funding needs through completion are expected to remain unchanged, helped by philanthropic support from the Sean M. Healey & AMG Center.
• As of May 22, 2026, 113 participants were assigned, 74 dosed, with 64 US sites active.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605271041PR_NEWS_USPR_____CN68965) on May 27, 2026, and is solely responsible for the information contained therein.